617. Long Acting Lipoglycopeptide Use in Veterans for Serious Gram-Positive Infections in the COVID Era

BACKGROUND: Dalbavancin and Oritavancin are semisynthetic lipoglycopeptides (LGP) that are FDA-approved for treatment of skin and soft tissue infections, but emerging data supports LGP use for other serious gram positive (GP) infections. We describe our experience with LGP during the COVID-19 pandem...

Descripción completa

Detalles Bibliográficos
Autores principales: Saldana, Carlos S, Goolsby, Tiffany, Epstein, Lauren H, Oliver, Nora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644193/
http://dx.doi.org/10.1093/ofid/ofab466.815

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644193/
http://dx.doi.org/10.1093/ofid/ofab466.815

Ejemplares similares